Deloitte’s US employees are joining the growing list of workers facing more expensive and less generous healthcare benefits.
According to an internal benefits guide seen by Business Insider, from January, the Big Four firm will no longer cover GLP-1 medication for weight-loss purposes through its medical plans.
At the same time, Deloitte employees will also face higher deductibles and out-of-pocket maximums under most health plans, the document said, meaning higher costs both before and after coverage kicks in.
The changes come as corporate America battles a widespread rise in health insurance costs for both employees and employers.
Deloitte told staff in the document that the changes “reflect the hard trade-offs of today’s cost environment,” and that there was a need “for shared responsibility in a few specific places where it’s become untenable for Deloitte to carry the cost alone.”
GLP-1 medication will remain covered when prescribed for diabetes and other covered medical conditions, the document said. For those seeking support with weight loss, Deloitte is instead offering employees access to a virtual lifestyle program called eMed that includes coaching and a $125-per-prescription employer contribution.
List prices for common GLP-1s like semaglutide and tirzepatide are generally in excess of $1,000, though direct purchase programs such as LillyDirect and government plans like TrumpRx mean the costs are often significantly lower.
TrumpRx, for instance, offers semaglutide injection pens under the Ozempic brand name for between $199 and $499.
A Deloitte spokesperson told Business Insider that, like other large employers, the firm has made select modifications where cost growth rates are no longer sustainable. The new support for weight-related uses of GLP-1s includes direct-from-manufacturer drug pricing, they said.
“Our financial commitment to our people and their families continues to grow,” the spokesperson said.
Have a tip to share? Contact this reporter via email at [email protected] or Signal at Polly_Thompson.89. Use a personal email address, a nonwork WiFi network, and a nonwork device; here’s our guide to sharing information securely.
Deloitte is also expanding certain healthcare coverage, including improving long-term disability protection and adding free annual eye exams to its company-paid discount vision program.
The benefits guide seen by Business Insider applies to what Deloitte calls its “Core, Domain, and Enterprise professionals,” which includes the majority of its traditional client-facing accountants, consultants, and technical specialists. The firm employs about 181,000 people in the US.
Health insurance costs are rising across the board
Michael Siluk/UCG/Universal Images Group via Getty Images
Deloitte’s changes to its coverage mirror a broader squeeze on US employer health plans. As healthcare costs and demand climb, everyone is paying more.
A 2026 health benefits survey from KFF found that workers on a family plan paid an average of $7,471 a year in premiums — a 9% increase from 2025. When accounting for employer contributions, family plan premiums totaled $28,303 in 2026, a roughly 5% increase from 2025.
More of Business Insider’s healthcare coverage
Restricting eligibility for GLP-1s has become a common route for employers looking to curb healthcare spending.
The drugs were developed to treat diabetes, but have become sought-after treatments for obesity and related chronic conditions. Aon, an insurance broker and employee-benefits consultancy, found that use of GLP-1s was up 75% in 2025.
The drugs’ rapid uptake and potential for long-term use have made them a costly pressure point for insurers and employer health plans. Aon found that 39% of employers planned to reduce or restrict GLP-1 coverage in 2026.
PwC and Starbucks are among those that have pulled back their coverage for weight-loss purposes this year.
Deloitte has also introduced broader benefit changes for a select group of staff. In April, Business Insider reported that for staff in Deloitte’s Center talent model — which mostly includes internal-facing admin roles — parental leave, annual PTO, and IVF funding would be reduced or eliminated as of January 1, 2027.
Deloitte’s Americas division was its slowest-growing region globally in the financial year ending May 31, 2026, with revenue rising 3.2%, down from 7.1% growth a year earlier.
